A. Burnett

发表

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

S. Robson, G. Drewes, M. Bantscheff, 2011, Nature.

Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia.

P. Vyas, A. Mead, T. Enver, 2011, Cancer cell.

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.

B. Smith, P. White, M. Levis, 2011, Blood.

Impact of karyotype on treatment outcome in acute myeloid leukemia.

D. Grimwade, A. Moorman, A. Burnett, 2004, Annals of hematology.

Expression of CD200 on AML blasts directly suppresses memory T-cell function

R. Hills, A. Burnett, S. Coles, 2012, Leukemia.

Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells

R. Hills, A. Burnett, S. Coles, 2012, Leukemia.

Chemotherapy‐induced cardiotoxicity: current practice and prospects of prophylaxis

A. Burnett, M. Gharib, 2002, European journal of heart failure.

Dielectrophoretic separation and enrichment of CD34+cell subpopulation from bone marrow and peripheral blood stem cells

R. Pethig, M. S. Talary, R. Pethig, 1995, Medical and Biological Engineering and Computing.

Review Articles (434 articles)

Bob Löwenberg, Pierre Fenaux, Hartmut Döhner, 2008 .

Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.

R. Hills, A. Burnett, K. Wheatley, 2007, Blood.

Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.

Lars Kjeldsen, Robert K Hills, Keith Wheatley, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A novel CSF‐1 binding factor in a patient in complete remission following cytotoxic therapy for lymphoma

E. Stanley, A. Burnett, G. B. Tennant, 1995, British journal of haematology.

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial.

R. Clark, A. Goldstone, A. Burnett, 2001, Blood.

Treatment of acute myeloid leukaemia in younger patients.

A. Burnett, 2001, Best practice & research. Clinical haematology.

A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.

R. Hills, N. Russell, M. Dennis, 2014, Blood.

Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.

F. Lo‐Coco, R. Hills, R. Clark, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inhibition of the LSD 1 ( KDM 1 A ) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia

Arthur, J. Dick, M. Minden, 2013 .

Prognostic and therapeutic relevance of c‐FLIP in acute myeloid leukaemia

P. Johnston, D. Longley, R. Hills, 2013, British journal of haematology.

A Randomised Comparison of the Sequential Addition of the FLT3 Inhibitor Lestaurtinib (CEP701) to Standard First Line Chemotherapy for FLT3-Mutated Acute Myeloid Leukemia: The UK Experience

R. Hills, N. Russell, M. Dennis, 2014 .

Gemtuzumab ozogamicin: time to resurrect?

E. Estey, R. Larson, F. Lo‐Coco, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

in younger patients with acute myeloid leukemia ozogamicin with intensive chemotherapy in induction and consolidation A feasibility study of simultaneous administration of gemtuzumab

A. Rohatiner, R. Clark, R. Chopra, 2013 .

Treatment of older patients with acute myeloid leukemia--new agents.

A. Burnett, U. Mohite, 2006, Seminars in hematology.

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

A. Rohatiner, R. Clark, A. Hunter, 2003 .

Acute myeloid leukemia: treatment of adults under 60 years.

A. Burnett, 2002, Reviews in clinical and experimental hematology.

Acute myeloid leukemia: therapeutic indications

A. Burnett, J. Kell, C. Rowntree, 2000, Current opinion in hematology.

AML: New Drugs but New Challenges.

R. Stone, A. Burnett, 2020, Clinical lymphoma, myeloma & leukemia.

Aminopeptidase inhibition by the novel agent CHR-2797 (tosedostat) for the therapy of acute myeloid leukemia.

D. Krige, A. Burnett, C. Pepper, 2011, Leukemia research.

OGG1 is a novel prognostic indicator in acute myeloid leukaemia

R. Hills, A. Burnett, R. Darley, 2010, Oncogene.

Mutant N-RAS Induces Erythroid Lineage Dysplasia in Human CD34+ Cells

A. Burnett, R. Darley, T. Hoy, 1997, The Journal of experimental medicine.

Establishing the presence of the t( 15; 17) in suspected acute promyelocytic leukaemia: cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial

D. Grimwade, E. Solomon, A. Goldstone, 1996, British journal of haematology.

The value of oral non-absorbed antibiotics in acute myeloid leukaemia

Melanie Williams, A. Burnett, G. Mcdonald, 1982 .

In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: fin

M. Tallman, S. Richards, L. Foroni, 2006, Blood.

XII/ECOG E2993 of more than 1500 patients from the international ALL trial: MRC UKALL Induction therapy for adults with acute lymphoblastic leukemia: results

S. Richards, H. Prentice, R. Chopra, 2008 .

Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.

M. Tallman, S. Richards, H. Prentice, 2005, Blood.

Analysis of the interaction of induction regimens with p-glycoprotein expression in patients with acute myeloid leukaemia: results from the MRC AML15 trial

R. Hills, N. Russell, M. Pallis, 2010, Blood cancer journal.

myeloid leukemia in patients 70 years or older care, including hydroxyurea, in the treatment of newly diagnosed acute A randomized phase 3 study of tipifarnib compared with best supportive

W. Jędrzejczak, H. Dombret, L. Möllgård, 2011 .

Analysis of the interaction of induction regimens with p-glycoprotein expression in patients with acute myeloid leukaemia: results from the MRC AML15 trial

R. Hills, N. Russell, M. Pallis, 2010, Blood cancer journal.

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.

W. Jędrzejczak, H. Dombret, G. Martinelli, 2007, Blood.

Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts

K. Mills, A. Burnett, C. Pepper, 2008, Haematologica.

Use of standardized flow cytometric determinants of multidrug resistance to analyse response to remission induction chemotherapy in patients with acute myeloblastic leukaemia

M. Pallis, J. Turzanski, S. Langabeer, 1999, British journal of haematology.

Increased circulating normal and BCR-ABL+Ve progenitor numbers in Philadelphia chromosome-positive acute myeloid leukaemia.

K. Mills, E. Owen-Jones, A. Burnett, 2002, Leukemia research.

The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target.

C. Fegan, P. Crooks, P. Brennan, 2008, Blood.

Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.

R. Hills, N. Russell, J. Cavenagh, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial.

R. Hills, N. Russell, M. Dennis, 2018, Blood.

Long Term Follow up from the NCRI AML17 Trial of Attenuated Arsenic Trioxide and ATRA Therapy for Newly Diagnosed and Relapsed Acute Promyelocytic Leukaemia

R. Hills, N. Russell, M. Dennis, 2016 .

Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial

R. Hills, N. Russell, A. Hunter, 2013, Leukemia.

abnormalities in normal human erythroid cells induced developmental - Protein kinase C mediates mutant N-Ras

A. Burnett, N. Omidvar, R. Darley, 2013 .

Running Title: PKC mediates N-Ras-induced dyserythropoiesis

A. Burnett, N. Omidvar, R. Darley, 2013 .

Protein kinase C mediates mutant N-Ras-induced developmental abnormalities in normal human erythroid cells.

A. Burnett, N. Omidvar, R. Darley, 2002, Blood.

Mutant RAS inhibits neutrophil but not macrophage differentiation and allows continued growth of neutrophil precursors.

A. Burnett, R. Darley, 1999, Experimental hematology.

Mutant RAS selectively promotes sensitivity of myeloid leukemia cells to apoptosis by a protein kinase C-dependent process.

D. Bowen, A. Burnett, R. Darley, 1998, Cancer research.

Oncogenic RAS genes impair erythroid differentiation of erythroleukaemia cells.

F. Zaker, A. Burnett, R. Darley, 1997, Leukemia research.

Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling

K. Mills, A. Burnett, A. Gilkes, 2008, British journal of haematology.

Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993.

M. Tallman, S. Richards, R. Chopra, 2006, Blood.

Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.

C. Craddock, R. Hills, N. Russell, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.

E. Estey, H. Dombret, S. Chevret, 2014, The Lancet. Oncology.

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

R. Hills, N. Russell, L. Kjeldsen, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial

R. Hills, N. Russell, R. Clark, 2016, Haematologica.

Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party.

T. A. Lister, J. Fitzgibbon, R. Hills, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HFE gene mutations in susceptibility to childhood leukemia: HuGE review

M. Worwood, A. Burnett, M. T. Dorak, 2005, Genetics in Medicine.

Hemochromatosis Gene in Leukemia and Lymphoma

M. Worwood, A. Burnett, M. Dorak, 2002, Leukemia & lymphoma.

Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone

R. Gray, R. Zittoun, A. Burnett, 1999, Cancer.

Treatment of acute myeloid leukemia: are we making progress?

A. Burnett, 2012, Hematology. American Society of Hematology. Education Program.

Hematologic malignancies: where do we stand in 2011?

H. Kantarjian, C. Schiffer, A. Burnett, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI

E. Estey, R. Hills, N. Russell, 2016, Haematologica.

Distinct poor prognostic subgroups of acute myeloid leukaemia, FLT3-ITD and P-glycoprotein-positive, have contrasting levels of FOXO1.

N. Russell, K. Mills, M. Pallis, 2014, Leukemia research.

RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years.

R. Hills, S. Langabeer, D. Linch, 2005, Blood.

The Novel Nuclear Factor-κB Inhibitor LC-1 Is Equipotent in Poor Prognostic Subsets of Chronic Lymphocytic Leukemia and Shows Strong Synergy with Fludarabine

C. Fegan, P. Brennan, C. Jordan, 2008, Clinical Cancer Research.

Expression of CD33 is a predictive factor for effect of Gemtuzumab Ozogamicin at different doses in adult acute myeloid leukemia

R. Hills, N. Russell, N. Khan, 2016, Leukemia.

Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial.

A. Burnett, K. Wheatley, J. Craig, 2006, Blood.

Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial.

R. Hills, M. McMullin, A. Goldstone, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The PDK1 master kinase is over-expressed in acute myeloid leukemia and promotes PKC-mediated survival of leukemic blasts

R. Hills, A. Burnett, R. Darley, 2014, Haematologica.

High dose cytarabine or transplantation for consolidation of younger patients with acute myeloid leukemia

A. Burnett, J. Kell, 2000, Current opinion in oncology.

Tailoring the treatment of acute myeloid leukemia.

A. Burnett, 1999, Current opinion in oncology.

Tailoring the treatment of acute myeloid leukemia.

A. Burnett, 1999, Current opinion in hematology.

Transplantation in first remission of acute myeloid leukemia.

A. Burnett, 1998, The New England journal of medicine.

TRANSPLANTATION OF UNPURGED AUTOLOGOUS BONE-MARROW IN ACUTE MYELOID LEUKAEMIA IN FIRST REMISSION

A. Burnett, C. Singer, G. Mcdonald, 1984, The Lancet.

Problems with up-front randomization in clinical trials.

R. Hills, A. Burnett, K. Wheatley, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A molecular analysis of the telomeric end of the major histocompatibility complex. DNA typing of HLA-A3 subtypes and -B7.

M. Worwood, A. Burnett, D. Wilson, 1995, Human immunology.

Alleles at D6S265 and D6S105 define a haemochromatosis‐specific genotype

M. Worwood, A. Burnett, C. Darke, 1994, British journal of haematology.

Ras-induced reactive oxygen species promote growth factor-independent proliferation in human CD34+ hematopoietic progenitor cells.

A. Burnett, P. James, R. Darley, 2010, Blood.

A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment

R. Hills, M. McMullin, A. Goldstone, 2007, Cancer.

REFINEMENT OF CYTOGENETIC CLASSIFICATION IN AML: DETERMINATION OF PROGNOSTIC SIGNIFICANCE OF RARE RECURRING CHROMOSOMAL ABNORMALITIES AMONGST 5635 YOUNGER ADULTS TREATED IN THE UK MRC TRIALS

R. Hills, D. Grimwade, C. Harrison, 2009 .

A simple genetic test identifies 90% of UK patients with haemochromatosis

Roger Williams, M. Worwood, Jennifer J. Pointon, 1997, Gut.

Serum Flt3 ligand is biomarker of progenitor cell mass and prognosis in acute myeloid leukemia

N. Russell, M. Grunwald, M. Levis, 2019, bioRxiv.

primary erythroid cells The AML1-ETO fusion gene promotes extensive self-renewal of human

J. Downing, A. Burnett, R. Darley, 2013 .

Hydroxyurea versus busulphan for chronic myeloid leukaemia: an individual patient data meta‐analysis of three randomized trials

H. Heimpel, J. Hasford, J. Godwin, 2000, British journal of haematology.

Adverse impact of bone marrow transplantation on quality of life in acute myeloid leukaemia patients; analysis of the UK Medical Research Council AML 10 Trial.

M. Watson, A. Goldstone, A. Burnett, 2004, European journal of cancer.

Identification of a retinoic acid responsive aldoketoreductase expressed in HL60 leukaemic cells

C. Bunce, K. Mills, M. Choudhry, 1998, FEBS letters.

Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.

R. Hills, N. Russell, M. Dennis, 2015, Blood.

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

R. Hills, N. Russell, A. Hunter, 2013, Leukemia.

The Addition of Arsenic Trioxide to Low Dose Ara-C in Older Patients with AML Does Not Improve Outcome

R. Hills, N. Russell, A. Hunter, 2011, Leukemia.

Allelic associations and homozygosity at loci from HLA-B to D6S299 in genetic haemochromatosis.

M. Worwood, D. Bowen, A. Burnett, 1995, Journal of medical genetics.

Key Regulatory Gene Expression in Erythroleukemia Differentiation

F. Zaker, A. Burnett, A. May, 2002 .

PLASMA EXCHANGE IN THE GUILLAIN-BARRÉ SYNDROME

A. Burnett, W. Durward, J. Reid, 1981, The Lancet.

FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia.

A. Mead, R. Hills, D. Linch, 2007, Blood.

Inhibition of mitochondrial function in HL60 cells is associated with an increased apoptosis and expression of CD14.

K. Mills, A. Burnett, A. Gilkes, 1999, Biochemical and biophysical research communications.

Autologous MHC-dependent leukaemia-reactive T lymphocytes in a patient with chronic myeloid leukaemia.

A. Burnett, T. Hoy, S. H. Lim, 1996, Leukemia.

The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML

R. Hills, N. Russell, A. Burnett, 2012, British journal of haematology.

T lymphocyte reconstitution following autologous bone marrow transplantation.

A. Burnett, C. Singer, P. Tansey, 1983, Clinical and experimental immunology.

Haemopoietic colony‐forming cells from peripheral blood stem cells harvests: cytokine requirements and lineage potential

A. Burnett, T. Hoy, P. Baines, 1994, British journal of haematology.

Treatment of small cell carcinoma of lung with late dosage intensification programmes containing cyclophosphamide and mesna.

R. Stevenson, N. Lucie, D. Cunningham, 1983, Cancer treatment reviews.

The impact of peripheral blood stem cell transplants (PBSCT) on platelet usage.

A. Burnett, R. Evely, R. B. Wood, 1997, Transfusion science.

CD200 as a prognostic factor in acute myeloid leukaemia

R. Hills, K. Mills, A. Burnett, 2007, Leukemia.

Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia.

G. Morgan, P. Sonneveld, U. Dührsen, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML.

R. Hills, R. Clark, A. Burnett, 2018, Blood advances.

CIP 2 Aand SETBP 1-mediated PP 2 A inhibition reveals AKT S 473 phosphorylation to be a new biomarker in AML

R. Hills, R. Clark, A. Burnett, 2018 .

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.

K Wheatley, D. Grimwade, C. Harrison, 1998, Blood.

Who is an “older” patient with acute myeloid leukaemia (AML)? An investigation of two NCRI/AML trials

R. Hills, A. Burnett, I. Mohamed, 2014, British journal of haematology.

Utility of a clinical risk score to identify high‐risk patients with de novo acute myeloid leukaemia in first remission after high‐dose cytarabine (HiDAC) based induction chemotherapy

R. Hills, A. Wei, A. Burnett, 2013, British journal of haematology.

the mutation mutations depends on the location of IDH2 The prognostic significance of

R. Hills, D. Linch, A. Burnett, 2012 .

Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12.

E. van den Berg, R. Hills, D. Grimwade, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.

R. Hills, D. Linch, A. Burnett, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA.

R. Hills, D. Linch, A. Goldstone, 2010, Blood.

The prognostic significance of IDH 1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT 3 / ITD status

R. Hills, D. Linch, A. Burnett, 2010 .

MRC trials in acute myeloblastic luekemia: Where have we got to?

A. Burnett, 2007, Leukemia & lymphoma.

The sensitivity of human cells expressing RUNX1-RUNX1T1 to chemotherapeutic agents

K. Mills, A. Burnett, R. Darley, 2006, Leukemia.

Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia.

R. Hills, A. Pizzey, K. Mills, 2005, Blood.

Autologous Peripheral Blood Stem Cell Transplantation in First Remission Adult Acute Myeloid Leukaemia--An Intention to Treat Analysis and Comparison of Outcome Using a Predictive Model Based on the MRC AML10 Cohort

J. Chang, R. Chopra, A. Burnett, 2003, Hematology.

Molecular characterisation of patients with APL entered into the UK MRC ATRA trial: Relationship of PML breakpoint with additional cytogenetic abnormalities and outcome [Abstract]

S. Langabeer, D. Grimwade, P. Gorman, 1997 .

Molecular MRD status and outcome after transplantation in NPM1 mutated AML: results from the UK NCRI AML17 study.

N. Potter, C. Craddock, R. Hills, 2019, Blood.

Comparison of ‘sequential’ versus ‘standard’ chemotherapy as re‐induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML‐R trial

A. Burnett, K. Wheatley, J. A. Liu Yin, 2001, British journal of haematology.

Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial.

D. Grimwade, E. Solomon, A. Goldstone, 1999, Blood.

Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival.

R. Hills, N. Russell, A. Hunter, 2013, Blood.

A randomised comparison of Clofarabine versus low dose Ara-C as first line treatment for older patients with AML [Abstract]

R. Hills, N. Russell, L. Kjeldsen, 2012 .

Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥ 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia

E. Estey, H. Dombret, G. Martinelli, 2012 .

The value of molecular stratification for CEBPA DM and NPM1 MUT FLT3 WT genotypes in older patients with acute myeloid leukaemia

R. Hills, D. Linch, Akbar Ali, 2015, British journal of haematology.

Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia.

R. Hills, A. Khwaja, D. Linch, 2014, Blood.

ferrochelatase gene in hematopoietic cells secondary to late-onset protoporphyria caused by deletion of a Photosensitivity and acute liver injury in myeloproliferative disorder

Geraint T. Williams, M. Badminton, G. Elder, 2013 .

Photosensitivity and acute liver injury in myeloproliferative disorder secondary to late-onset protoporphyria caused by deletion of a ferrochelatase gene in hematopoietic cells.

Geraint T. Williams, M. Badminton, G. Elder, 2006, Blood.

Role of allogeneic and autologous hematopoietic stem cell transplantation in acute myeloid leukemia.

A. Burnett, J. Kell, C. Rowntree, 2000, International journal of hematology.

Molecular evidence for a common leukaemic progenitor in acute mixed lymphoid and myeloid leukaemia

S. John, A. Burnett, J. Whittaker, 1996, British journal of haematology.

Retinoic Acid: Result of the Randomized MRC Trial All-Trans Predict Prognosis in Acute Promyelocytic Leukemia Treated With Presenting White Blood Cell Count and Kinetics of Molecular Remission

D. Grimwade, E. Solomon, A. Goldstone, 2013 .

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Presenting White Blood Cell Count and Kinetics of Molecular Remission Predict Prognosis in Acute Promyelocytic Leukemia Treated With All- Trans Retinoic Acid: Result of the Randomized MRC Trial

D. Grimwade, E. Solomon, A. Goldstone, 2022 .

Further evidence that the site of the breakpoint in the major breakpoint cluster region (M-bcr) may be a prognostic indicator.

K. Mills, A. Burnett, S. Hynds, 1989, Leukemia.

Twenty five years of UK trials in acute myeloid leukaemia: what have we learned?

R. Hills, N. Russell, A. Burnett, 2019, British journal of haematology.

Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission.

R. Hills, N. Russell, A. Hunter, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial.

D. Grimwade, E. Solomon, A. Goldstone, 1999, Blood.

Identification of PML/RARα rearrangements in suspected acute promyelocytic leukemia using fluorescence in situ hybridization of bone marrow smears: a comparison with cytogenetics and RT-PCR in MRC ATRA trial patients

A. Chase, D. Grimwade, A. Goldstone, 2000, Leukemia.

Karyotypically defined risk groups in acute myeloid leukaemia.

A. Burnett, 1994, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients

R. Hills, N. Russell, M. Dennis, 2021, Blood advances.

Less Intensive 1 (LI1) Trial: A Randomized Phase II/III Clinical Trial in Approximately 1000 Elderly Patients With Acute Myeloid Leukaemia (AML) Deemed Not Suitable for Intensive Chemotherapy

R. Hills, N. Russell, M. Dennis, 2021 .

A randomised evaluation of low‐dose cytosine arabinoside (ara‐C) plus tosedostat versus low‐dose ara‐C in older patients with acute myeloid leukaemia: results of the LI‐1 trial

R. Hills, N. Russell, M. Dennis, 2021, British journal of haematology.

Randomised evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients

R. Hills, N. Russell, M. Dennis, 2021 .

Treatment of Older Patients With Newly Diagnosed AML Unfit for Traditional Therapy

A. Burnett, 2018, Clinical lymphoma, myeloma & leukemia.

The Challenge of AML in Older Patients

A. Burnett, 2013, Mediterranean journal of hematology and infectious diseases.

European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy.

R. Hills, N. Russell, M. Dennis, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The importance of diagnostic cytogenetics in older patients with AML: Analysis of 922 patients entered into the MRC AML 11 trial.

D. Grimwade, A. Goldstone, A. Burnett, 1999 .

Low dose Ara-C versus low Dose Ara-C and Tipifarnib: result of the UK NCRI AML16 "Pick a Winner" comparison [Abstract]

R. Hills, N. Russell, A. Burnett, 2008 .

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.

R. Hills, N. Russell, L. Kjeldsen, 2017, Blood.

com-Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study

E. Estey, R. Schlenk, R. Hills, 2019 .

Lack of benefit of G-CSF on complete remission and possible increased relapse risk in AML: An MRC study of 800 patients [Abstract]

A. Burnett, A. Prentice, K. Wheatley, 1997 .

GCSF augments post-progenitor proliferation in serum-free cultures of myelodysplastic marrow while ATRA enhances maturation.

A. Burnett, T. Hoy, P. Baines, 1998, Leukemia research.

Frequency of clonal remission in acute myeloid leukaemia

D. Linch, A. Goldstone, A. Burnett, 1993, The Lancet.

The treatment of AML: Current status and novel approaches

A. Burnett, 2005, Hematology.

Prognosis of myelodysplasic patients: non‐parametric multiple regression analysis of populations stratified by mean corpuscular volume and marrow myeloblast number

A. Burnett, G. B. Tennant, A. Al-Sabah, 2002, British journal of haematology.

Responsiveness to stem cell factor (SCF) of peripheral blood colony-forming cells from patients with myelodysplastic syndromes (MDS).

D. Bowen, A. Burnett, C. Tang, 1995, Leukemia research.

Attempts to Optimise Induction and Consolidation Chemotherapy in Patients with Acute Myeloid Leukaemia: Results of the MRC AML15 Trial.

R. Hills, N. Russell, L. Kjeldsen, 2009 .

A Sensitive Risk Score for Directing Treatment in Younger Patients with AML.

R. Hills, A. Goldstone, A. Burnett, 2006 .

GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations

J. Fitzgibbon, R. Hills, D. Linch, 2013, British journal of haematology.

Aberrant expression of p21RAS but not p120GAP is a common feature of myelodysplasia.

A. Burnett, R. Darley, T. Hoy, 1995, Leukemia.

The C282Y mutation of HFE is another male-specific risk factor for childhood acute lymphoblastic leukemia.

M. Worwood, A. Burnett, B. Gibson, 1999, Blood.

Thymus‐leukaemia antigens: The haemochromatosis gene product?

M. Worwood, A. Burnett, M. T. Dorak, 1994, Immunology and cell biology.

Human major histocompatibility complex contains several leukemia susceptibility genes.

M. Worwood, K. Mills, D. Gaffney, 1994, Leukemia & lymphoma.

A Multicentre Phase II Study of the Aminopeptidase Inhibitor, CHR- 2797, in the Treatment of Elderly and/or Previously Treated patients with Acute Myeloid Leukemia.

G. Morgan, P. Sonneveld, M. Jongen‐Lavrencic, 2008 .

No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials.

R. Hills, N. Russell, N. Khan, 2018, Blood.

HFE Gene Mutation Status Predicts Response to Gemtuzumab Ozogamicin in AML

H. Dombret, R. Hills, C. Preudhomme, 2015 .

A Phase 2 Evaluation of Single Agent Clofarabine as First Line Treatment for Older Patients with AML Who Are Not Considered Fit for Intensive Chemotherapy.

N. Russell, A. Burnett, D. Milligan, 2004 .

Reproducible measurements of AML blast p-glycoprotein function in 2 center analyses.

N. Russell, M. Pallis, M. Grundy, 2005, Blood.

Gemtuzumab ozogamicin in (KMT2A)‐rearranged adult acute myeloid leukaemia (AML) in the UK Medical Research Council AML15 and AML16 trials

R. Hills, N. Russell, A. Burnett, 2021, British journal of haematology.

Childhood Acute Lymphoblastic Leukemia Is Another Male-Specific Risk Factor for HFE The C282Y Mutation of

M. Worwood, A. Burnett, M. T. Dorak, 2011 .

New induction and postinduction strategies in acute myeloid leukemia

A. Burnett, 2012, Current opinion in hematology.

What happens subsequently in AML when cytogenetic abnormalities persist at bone marrow harvest? Results of the 10th UK MRC AML Trial

D. Grimwade, A. Burnett, K. Wheatley, 1997, Bone Marrow Transplantation.

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

E. Estey, H. Döhner, H. Dombret, 2018, The Lancet. Oncology.

Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation

E. Estey, H. Döhner, H. Dombret, 2012 .

Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses

R. Hills, N. Russell, L. Kjeldsen, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation.

D. Cunningham, D. Linch, R. Chopra, 1993, Bone marrow transplantation.

Autologous bone marrow transplant in the treatment of acute leukaemia.

A. Burnett, 1991, Bailliere's clinical haematology.

Seronegative blood products prevent primary cytomegalovirus infection after bone marrow transplantation.

S. Mackinnon, A. Burnett, S. Cameron, 1988, Journal of clinical pathology.

Autologous bone marrow transplantation in acute leukaemia.

A. Burnett, 1988, Leukemia research.

Clinical studies of ABMT in acute myeloid leukaemia.

D. Linch, A. Burnett, 1986, Clinics in haematology.

Autologous Bone Marrow Transplantation in Acute Myeloid Leukaemia in First Remission

A. Burnett, C. Singer, G. Mcdonald, 1984 .

Haematological reconstitution following high dose and supralethal chemo‐radiotherapy using stored, non‐cryopreserved autologous bone marrow

A. Burnett, S. Banham, T. Sheehan, 1983, British journal of haematology.

Control of pH in human long‐term bone marrow cultures with low‐glucose medium containing zwitterion buffer lengthens the period of haemopoietic activity

A. Burnett, G. B. Tennant, R. Bailey‐Wood, 2000, British journal of haematology.

Correlation of M-bcr breakpoint with different chromosomal abnormalities in blast crisis Ph1-positive CML.

K. Mills, A. Burnett, J. Stewart, 1991, Leukemia research.

Optimized Retroviral Transduction Protocol Which Preserves the Primitive Subpopulation of Human Hematopoietic Cells

A. Burnett, R. Darley, A. Tonks, 2008, Biotechnology progress.

The NF-κB Inhibitor LC-1 Has Single Agent Activity in Multiple Myeloma Cells and Synergizes with Bortezomib

C. Fegan, P. Crooks, A. Burnett, 2010, Molecular Cancer Therapeutics.

Low Dose Ara-C Versus Hydroxyurea with or without Retinoid in Older Patients Not Considered Fit for Intensive Chemotherapy: The UK NCRI AML14 Trial.

M. McMullin, A. Goldstone, A. Burnett, 2004 .

Attempts to modulate chemoresistance in older patients with AML using PSC-833 - Results of the LRF AML14 trial

R. Hills, N. Russell, M. Pallis, 2003 .

Long‐term survival of myelodysplastic patients with macrocytosis

I. Cavill, A. Burnett, G. B. Tennant, 2004, British journal of haematology.

Expression of AML1-ETO in human myelomonocytic cells selectively inhibits granulocytic differentiation and promotes their self-renewal

A. Burnett, R. Darley, A. Tonks, 2004, Leukemia.

A randomised comparison of FLAG‐Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial

R. Hills, N. Russell, L. Kjeldsen, 2022, British journal of haematology.

Lestaurtinib FLT3 Inhibitory Activity Is Modulated by Concomitant Azole Therapy and May Influence Relapse Risk.

R. Hills, M. Levis, D. Small, 2009 .

Overgrowth of a leukemic culture by a minor CD34+ population.

A. Burnett, T. Hoy, P. Baines, 1998, Leukemia research.

A comparison of Daunorubicin/Ara-C (DA) versus Daunorubicin/Clofarabine (DClo) and two versus three courses of total treatment for older patients with AML and high risk MDS: results of the UK NCRI AML16 Trial [Abstract]

R. Hills, N. Russell, L. Kjeldsen, 2012 .

RUNX1-RUNX1T1 Induces Over-Expression of γ-Catenin in Human CD34+ Cells, Increasing Self Renewal and Impairing Granulocytic Differentiation.

K. Mills, A. Burnett, A. Gilkes, 2005 .

Refractory anaemia with preleukaemic polyclonal haemopoiesis and the emergence of monoclonal erythropoiesis on disease progression

D. Bowen, A. Burnett, A. May, 1995, British journal of haematology.

Non-dysplastic myelodysplasia?

A. Burnett, G. B. Tennant, P. Thompson, 1994, Leukemia.

Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia.

R. Hills, N. Russell, A. Burnett, 2016, Blood.

Mutant N-RAS induces erythroid lineage dysplasia in human CD34(+) progenitor cells

A. Burnett, R. Darley, T. Hoy, 1995 .

Nuclear factor‐κB as a potential therapeutic target for the novel cytotoxic agent LC‐1 in acute myeloid leukaemia

P. Crooks, K. Mills, A. Burnett, 2008, British journal of haematology.

Quantitation of Leukemic Stem Cell Populations Predicts Clinical Outcome in Acute Myeloid Leukaemia

I. Weissman, P. Vyas, C. Craddock, 2011 .

Preliminary report of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg (R)) given in combination with cytarabine and daunorubicin in patients with acute myeloid leukemia

J. Esteve, M. Berger, M. Tallman, 2001 .

Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial

C. Craddock, R. Hills, N. Russell, 2021, Haematologica.

Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG

R. Hills, K. Kerr, N. Russell, 2022, Leukemia & lymphoma.

Cord Blood-Derived Quiescent CD34+ Cells Are More Transcriptionally Matched to AML Blasts Than Cytokine-Induced Normal Human Hematopoietic CD34+ Cells.

R. Hills, A. Whetton, A. Burnett, 2015, Gene expression.

Myelodysplastic bone marrow stroma is defective in its ability to sustain normal stem cell growth

A. Burnett, G. B. Tennant, W. Kell, 1997 .

needle * Two modified Rosenthal marrow harvest needles or equivalent * One sternal aspiration needle * Eight 30 ml plastic disposable syringes *

A. Burnett, R. Jones, 2004 .

ACP Broadsheet No 134: December 1992. How to harvest bone marrow for transplantation.

A. Burnett, R. Jones, 1992, Journal of clinical pathology.

How toharvest bonemarrow fortransplantation

A. Burnett, R. Jones, 1992 .

Autologous bone marrow transplantation with monoclonal antibody purged marrow for high risk acute lymphoblastic leukemia.

H. Prentice, M. Brenner, A. Burnett, 1989, Leukemia.

Impact of Marrow Transplantation in Acute Myeloid Leukemia in First Complete Remission: Experience from MRC AML-10 Trial

A. Burnett, K. Wheatley, A. Goldstone, 1997 .

Autologous Bone Marrow Transplantation in First Remission AML using Non-Purged Marrow — Update

A. Burnett, S. Mckinnon, 1986 .

Increasing methylation of the calcitonin gene during disease progression in sequential samples from CML patients.

K. Mills, A. Burnett, B. Guinn, 1996, Leukemia research.

RUNX1–ETO deregulates the proliferation and growth factor responsiveness of human hematopoietic progenitor cells downstream of the myeloid transcription factor, MYCT1

A. Burnett, R. Darley, A. Tonks, 2011, Leukemia.

Influence of the major histocompatibility complex on age at onset of chronic lymphoid leukaemia

K. Mills, A. Burnett, M. T. Dorak, 1996 .

Molecular mimicry of an HLA-DR53 epitope by viruses.

A. Burnett, M. Dorak, 1994, Immunology today.

MHC class III polymorphisms in selection of donors for BMT.

K. Mills, E. Chalmers, A. Burnett, 1993, Bone marrow transplantation.

The Addition of Gemtuzumab Ozogamicin to Intensive Chemotherapy in Older Patients with AML Produces a Significant Improvement in Overall Survival: Results of the UK NCRI AML16 Randomized Trial

R. Hills, N. Russell, L. Kjeldsen, 2011 .

The MEK inhibitor, PD98059, reduces survival but does not block acute myeloid leukemia blast maturation in vitro

M. Hallett, A. Burnett, T. Hoy, 2000, European journal of haematology.

Does all-transretinoic acid (ATRA) have a role in non-APL acute myeloid leukaemia?: Results from 1666 patients in three MRC trials [Abstract]

R. Hills, A. Goldstone, A. Burnett, 2004 .

Fludarabine, cytosine arabinoside, granulocyte‐colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes

A. Burnett, K. Wheatley, D. Milligan, 2004, British journal of haematology.

randomized trial G-CSF and ATRA are not beneficial: results of the MRC AML-HR chemotherapy in high-risk acute myeloid leukemia, and addition of Fludarabine and cytosine are less effective than standard ADE

A. Burnett, K. Wheatley, J. Craig, 2013 .

SAFETY OF DIMETHYLSULPHOXIDE

A. Burnett, T. Sheehan, G. Mcdonald, 1981, The Lancet.

Use of autologous bone marrow transplantation in acute myeloid leukemia.

A. Burnett, 1987, Haematology and blood transfusion.

Nature of HLA-associated predisposition to childhood acute lymphoblastic leukemia.

G. Owen, K. Mills, A. Burnett, 1995, Leukemia.

Homozygous MHC genotypes and longevity.

K. Mills, D. Gaffney, A. Burnett, 1994, Human heredity.

A Phase II Open-Label, Ac220 Monotherapy Efficacy Study In Patients with Refractory/Relapsed Flt3-Itd Positive Acute Myeloid Leukemia: Updated Interim Results

E. Estey, H. Döhner, H. Dombret, 2011 .

promising therapeutic target disease progression in chronic lymphocytic leukemia and represents a B subunit Rel A is associated with in vitro survival and clinical κ The NF

P. Crooks, P. Brennan, C. Jordan, 2013 .

The Impact of FLT3-ITD and NPM1 Mutational Status on the Outcome of ATRA Therapy in Patients with Non-APL AML: Results of the UK MRC AML12 Trial

R. Hills, D. Linch, M. Lazenby, 2008 .

Plasma exchange in non-haemophiliac patients with inhibitors to factor VIIIC.

A. Burnett, I. Walker, J. Davidson, 1981, British medical journal.

Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia.

Robert K Hills, R. Hills, N. Russell, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Consensus Conference on Intensive Chemotherapy Plus Hematopoietic Stem-Cell Transplantation in Malignancies: Lyon, France, June 4-6, 1993.

B. Coiffier, A. Burnett, T. Philip, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Consensus conference on intensive chemotherapy plus hematopoietic stem cell transplantation in malignancies, Lyon, June 4-6, 1993.

B. Coiffier, A. Burnett, T. Philip, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

In vitro drug resistance in acute myeloid and chronic B-lymphocytic leukaemic blasts and in normal blood and marrow populations.

A. Burnett, J. Whittaker, T. Hoy, 1994, Leukemia research.

Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia

Martin Dugas, Hans-Ulrich Klein, Kevin Petrie, 2012, Nature Medicine.

An Operational Definition of Primary Refractory Acute Myeloid Leukaemia Which Allows Early Identification of Patients for Whom Allogeneic Stem Cell Transplantation Represents the Only Curative Therapy

P. Vyas, C. Craddock, R. Hills, 2015 .

Molecular Detection of Minimal Residual Disease Provides the Most Powerful Independent Prognostic Factor Irrespective of Clonal Architecture in Nucleophosmin (NPM1) Mutant Acute Myeloid Leukemia

P. Vyas, M. Simpson, R. Hills, 2014 .

Mutant N-RAS blocks granulocytic differentiation of human CD34(+) cells [Abstract]

A. Burnett, R. Darley, T. Hoy, 1998 .

Subclinical pulmonary function defects following autologous and allogeneic bone marrow transplantation: relationship to total body irradiation and graft-versus-host disease.

R. Stevenson, R. Tait, A. Burnett, 1991, International journal of radiation oncology, biology, physics.

The Addition Of Gemtuzumab Ozogamicin (GO) To Induction Chemotherapy Reduces Relapse and Improves Survival In Patients Without Adverse Risk Karyotype: Results Of An Individual Patient Meta-Analysis Of The Five Randomised Trials

E. Estey, H. Dombret, S. Chevret, 2013 .

The Addition of Gemtuzumab Ozogamicin to Low Dose Ara-C Improves Remission Rates but Not Survival: Results of the UK LRF AML14 and NCRI AML16 “Pick a Winner” Comparison

R. Hills, N. Russell, A. Hunter, 2010 .

Trisenox (R) (arsenic trioxide) in patients with myelodysplastic syndromes (MDS): Preliminary results of a phase I/II study.

H. Dombret, P. Fenaux, N. Vey, 2004 .

Detection of minimal residual disease (MRD) in APL by "real-time" RT-PCR: Analysis of cases entered into the UK MRC ATRA trial.

A. Wheatley, D. Grimwade, E. Solomon, 1999 .

Stem Cell Transplants in Acute Myeloid Leukaemia (AML)

A. Burnett, K. Wheatley, L. Robinson, 1998 .

Allo and auto BMT reduce relapse risk in AML in CR1 but do not significantly improve overall survival Results of the MRC AML 10 trial

R. Gray, A. Burnett, K. Wheatley, 1996 .

A simple, robust and highly predictive prognostic index for the determination of risk directed therapy in acute myeloid leukaemia (AML) derived from the United Kingdom medical research council (MRC) AML10 trial.

R. Gray, A. Burnett, K. Wheatley, 1995 .

Sustained growth in long trm bone-marrow culture of AML remission marrow predicts a high probability of remaining relapse-free after auto BMT in first complete remission

A. Burnett, M. Alcorn, S. Graham, 1993 .

Effectiveness of Clofarabine in Elderly AML Patients with Adverse Cytogenetics Unfit for Intensive Chemotherapy.

M. Baccarani, R. Hills, N. Russell, 2006 .

A randomised evaluation of low‐dose Ara‐C plus pegylated recombinant arginase BCT‐100 versus low dose Ara‐C in older unfit patients with acute myeloid leukaemia: Results from the LI‐1 trial

N. Russell, M. Dennis, M. Copland, 2022, British journal of haematology.

Evaluation of Prospective Detection of PML-RARA and RARA-PML Fusion Transcripts by Real-Time Quantitative PCR (RQ-PCR) To Direct Pre-Emptive Therapy with Arsenic Trioxide (ATO) in Acute Promyelocytic Leukemia (APL) Patients Treated in the UK MRC AML15 Trial.

R. Hills, D. Grimwade, E. Solomon, 2007 .

Iron overload and liver dysfunction after allogeneic or autologous bone marrow transplantation.

A. Burnett, S. Cameron, I. Franklin, 1996, Bone marrow transplantation.

Investigation and management of pulmonary infiltrates following bone marrow transplantation: an eight year review.

R. Stevenson, A. Burnett, J. Campbell, 1993, Thorax.

Investigation andmanagement ofpulmonary infiltrates following bonemarrow transplantation: an eightyearreview

R. Stevenson, A. Burnett, J. Campbell, 1993 .

Pulmonary infiltrates following bone marrow transplantation Table 2 Clinical presentation ofpulmonary infiltrates in 27 patients following bone marrow transplantation

R. Stevenson, A. Burnett, J. Campbell, 2022 .

Frequency of CBF beta/MYH11 fusion transcripts in patients entered into the U.K. MRC AML trials. The MRC Adult Leukaemia Working Party.

S. Langabeer, D. Linch, A. Burnett, 1997, British journal of haematology.

Autologous bone marrow transplants: Different indications in Europe and North America

J. Armitage, A. Hagenbeek, N. Gale, 1989 .

Mapping of breakpoints, and relationship to BCR-ABL RNA expression, in Philadelphia-chromosome-positive chronic myeloid leukaemia patients with a breakpoint around exon 14 (b3) of the BCR gene.

K. Mills, A. Burnett, A. Sproul, 1991, Leukemia.

Applicability of a "Pick a Winner" trial design to acute myeloid leukemia.

Robert K Hills, R. Hills, A. Burnett, 2011, Blood.

Two new polymorphisms but no mutations of the KIT gene in patients with myelodysplasia at positions corresponding to human FMS and murine W locus mutational hot spots.

C. Decastro, D. Bowen, A. Burnett, 1993, Leukemia.

Current issues in autografting for acute myeloid leukaemia.

A. Burnett, 1992, Leukemia & lymphoma.

Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.

E. Estey, H. Döhner, T. Naoe, 2019, Blood.

An Evaluation of 17 Years of Low Dose Cytarabine As Therapy for AML Patients Not Fit for Intensive Treatment, Including Patients with Adverse Cytogenetics, Shows Improving Survival, Potential Underutilisation and Highlights the Need for New Therapy

R. Hills, N. Russell, M. Dennis, 2017 .

Influence of genetic predisposition to thrombosis on natural history of acute promyelocytic leukaemia

S. Langabeer, D. Grimwade, A. Goldstone, 1997, British journal of haematology.

Frequency of clonal remission in acute myeloid leukemia

D. Linch, A. Burnett, A. Goldstone, 1993 .

cytometry. IV. CD34 overexpression in acute myelogenous leukemia Leukemia-associated changes identified by quantitative flow

G. Janossy, A. Goldstone, D. Swirsky, 2011 .

Getting to the heart of improving outcomes for patients with acute promyelocytic leukemia.

D. Grimwade, A. Burnett, 2012, Oncology.

Reply to S. Nagai et al

F. Lo‐Coco, R. Hills, D. Grimwade, 2010 .

Idarubicin and ATRA Is as Effective as MRC Chemotherapy in Patients with Acute Promyelocytic Leukaemia with Lower Toxicity and Resource Usage: Preliminary Results of the MRC AML15 Trial.

R. Hills, N. Russell, A. Hunter, 2007 .

Optimal induction and post-remission therapy for acute myeloid leukemia.

A. Burnett, 2012, Leukemia supplements.

Combination of a mitogen‐activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion‐based residual disease and prevents re‐expansion of FLT3‐ITD acute myeloid leukaemia

R. Hills, M. Lazenby, A. Burnett, 2020, British journal of haematology.

Who may give blood?

A. Burnett, E. Follett, R. Crawford, 1987, British medical journal.

Therapeutic advances in acute myeloid leukemia.

B. Löwenberg, A. Burnett, M. Wetzler, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Comparison of Daunorubicin/Ara-C Versus Daunorubicin/Clofarabine As Induction Treatment in Older Patients with Aml and High Risk Mds: Long Term Results of the Uk Ncri Aml16 Trial in 806 Patients

R. Hills, N. Russell, M. Dennis, 2015 .

A Comparison of Single Dose Gemtuzumab Ozogamicin 3mg/m2 and 6mg/m2 Combined with Induction Chemotherapy in Younger Patients with AML: Data from the UK NCRI AML17 Trial

R. Hills, N. Russell, M. Dennis, 2014 .

Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial

Keith Wheatley, R. Gray, A. Goldstone, 1998, The Lancet.

The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial

A. Goldstone, A. Burnett, K. Wheatley, 2002, British journal of haematology.

An efficient one-pot multicomponent approach to 5-amino-7-aryl-8-nitrothiazolo[3,2-a]pyridines

A. Westwell, A. Burnett, C. Altug, 2011 .

An Efficient One‐Pot Multicomponent Approach to 5‐Amino‐7‐aryl‐8‐nitrothiazolo[3,2‐a]pyridines.

A. Westwell, A. Burnett, C. Altug, 2012 .

Unified classification and risk-stratification in Acute Myeloid Leukemia

P. Campbell, L. Bullinger, K. Döhner, 2022, Nature Communications.

Assessment of Minimal Residual Disease in Standard-Risk AML.

Yashma Patel, Robert K Hills, Hassan Farah, 2016, The New England journal of medicine.

Resistance Prediction in AML: Analysis of 4,601 Patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center

Bob Löwenberg, Elihu H. Estey, Megan Othus, 2014, Leukemia.

PLASMA-EXCHANGE COMBINED WITH IMMUNOSUPPRESSIVE THERAPY IN MYASTHENIA GRAVIS

J. Simpson, R. Shakir, P. Behan, 1979, The Lancet.

Acute myeloid leukaemia

Asim Khwaja, Rosemary E. Gale, David C. Linch, 2016, Nature Reviews Disease Primers.

The European LeukemiaNet: achievements and perspectives

P. Schrotz-King, H. Döhner, H. Einsele, 2011, Haematologica.

Invasive aspergillosis localised to the colon presenting as toxic megacolon

A. Burnett, J. Rees, J. Kell, 2007, European journal of haematology.

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

R. Hills, D. Grimwade, C. Harrison, 2010, Blood.

P. Sonneveld, E. Vellenga, B. van der Holt, 2007, Annals of Hematology.

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.

D. Grimwade, C. Harrison, A. Goldstone, 2001, Blood.

Iron absorption from a natural mineral water (Spatone Iron-Plus).

M. Worwood, A. Burnett, W. D. Evans, 2010, Clinical and laboratory haematology.

No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.

R. Hills, D. Linch, A. Burnett, 2005, Blood.

Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study

E. Estey, R. Schlenk, R. Hills, 2019, Haematologica.

The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine

A. Burnett, S. Knapper, E. Walsby, 2011, Haematologica.

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

E. Estey, H. Döhner, T. Naoe, 2009, Blood.

status at diagnosis previously untreated acute myeloid leukemia (AML), in relation to MDR1 daunorubicin and cytarabine in the treatment of elderly patients with The value of the MDR1 reversal agent PSC-833 in addition to

E. Vellenga, M. Fey, G. Ossenkoppele, 2013 .

The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.

P. Sonneveld, E. Vellenga, B. van der Holt, 2005, Blood.

The value of the MDR 1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia ( AML ) , in relation to MDR 1 status at diagnosis

E. Vellenga, M. Fey, P. Piccaluga, 2022 .

Changing p53 mutations with the evolution of chronic myeloid leukaemia from the chronic phase to blast crisis.

K. Mills, A. Burnett, B. Guinn, 1995, Leukemia research.

Progress in the treatment of acute myeloid leukemia

H. Kantarjian, F. Ravandi, A. Burnett, 2007, Cancer.

Major histocompatibility complex, t-complex, and leukemia

A. Burnett, M. T. Dorak, M. Dorak, 1992, Cancer Causes & Control.

fit for intensive chemotherapy treatment for older patients with acute myeloid leukemia not considered A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line

R. Clark, M. Levis, D. Small, 2013 .

FLT3 inhibition as a targeted therapy for acute myeloid leukemia

Bob Löwenberg, F. Lo‐Coco, M. Sanz, 2009, Current opinion in oncology.

The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases.

K. Mills, A. Burnett, A. Gilkes, 2006, Blood.

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.

Richard Clark, R. Clark, M. Levis, 2004, Blood.

Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia.

T. Haferlach, R. Hills, S. Schnittger, 2015, Blood.

Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia

K. Mills, A. Burnett, A. Gilkes, 2007, Leukemia.

The AML1-ETO fusion gene promotes extensive self-renewal of human primary erythroid cells.

J. Downing, A. Burnett, R. Darley, 2003, Blood.

The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status.

R. Hills, D. Linch, A. Burnett, 2010, Blood.

Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML

P. Campbell, L. Bullinger, H. Döhner, 2019, The Journal of experimental medicine.

The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias

P. Vyas, R. Hills, E. Bone, 2016, OncoTarget.

Simpson's Paradox and the Impact of Different DNMT3A Mutations on Outcome in Younger Adults With Acute Myeloid Leukemia.

R. Hills, D. Linch, A. Burnett, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Leukemia-associated changes identified by quantitative flow cytometry. IV. CD34 overexpression in acute myelogenous leukemia M2 with t(8;21).

G. Janossy, A. Goldstone, D. Swirsky, 1996, Blood.

Major histocompatibility t-complex, and leukemia complex,

A. Burnett, M. Dorak, 1992 .

Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia.

P. Freemont, D. Sheer, S. Langabeer, 1997, Blood.

γ-Catenin is overexpressed in acute myeloid leukemia and promotes the stabilization and nuclear localization of β-catenin

A. Burnett, R. Darley, A. Tonks, 2012, Leukemia.

Integrated Nuclear Proteomics and Transcriptomics Identifies New High Frequency Dysregulated Transcription Factors in AML

R. Hills, A. Williamson, A. Whetton, 2014 .

A simple, robust, validated and highly predictive index for the determination of risk‐directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial

R. Gray, A. Goldstone, A. Burnett, 1999, British journal of haematology.

Genome-wide association study identi ﬁ es susceptibility loci for acute myeloid leukemia

Lara E Sucheston-Campbell, Lara E. Sucheston-Campbell, C. Gieger, 2022 .

Treatment of acute myeloid leukaemia.

A. Burnett, 2013, Clinical medicine.

Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia

I. Weissman, P. Vyas, C. Craddock, 2013, Leukemia.

The role of PKC and PDK1 in monocyte lineage specification by Ras.

A. Burnett, R. Darley, J. Fisher, 2007, Blood.

Increased heterozygosity for MHC class II lineages in newborn males

K. Mills, A. Burnett, M. T. Dorak, 2002, Genes and Immunity.

Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.

H. Dombret, M. Dennis, P. Fenaux, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide

E. Estey, R. Schlenk, R. Hills, 2017, Leukemia.

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

Adam J Mead, Robert K Hills, A. Mead, 2008, Blood.

Current Controversies: Which Patients With Acute Myeloid Leukaemia Should Receive A Bone Marrow Transplantation? – An Adult Treater's View

A. Burnett, Alan K. Burnett , 2002, British journal of haematology.

Mediated by Ras Inhibition of Myeloid Differentiation Ral Is both Necessary and Sufficient for the

Richard, A. Burnett, N. Omidvar, 2014 .

Ral Is both Necessary and Sufficient for the Inhibition of Myeloid Differentiation Mediated by Ras

A. Burnett, N. Omidvar, R. Darley, 2006, Molecular and Cellular Biology.

Acute myeloid leukemia in adults

A. Burnett, 2004 .

The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia

R. Hills, D. Linch, A. Burnett, 2013, Leukemia.

Sequential Influences of Leukemia-Specific and Genetic Factors on P-Glycoprotein Expression in Blasts from 817 Patients Entered into the National Cancer Research Network Acute Myeloid Leukemia 14 and 15 Trials

N. Russell, M. Pallis, M. Grundy, 2007, Clinical Cancer Research.

patients with acute myeloid leukemia and interaction with NPM1 mutations in a large cohort of young adult The impact of FLT3 internal tandem duplication mutant level, number, size

A. Mead, R. Hills, D. Linch, 2013 .

Relationship between FLT 3 mutation status , biologic characteristics , and response to targeted therapy in acute promyelocytic leukemia

R. Hills, A. Pizzey, K. Mills, 2005 .

Mutation of the Wilms’ Tumor 1 Gene Is a Poor Prognostic Factor Associated with Chemoresistance in Normal Karyotype Acute Myeloid Leukemia.

T. A. Lister, J. Fitzgibbon, R. Hills, 2007 .

Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report.

E. Estey, J. Radich, S. Meshinchi, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Refinement of cytogenetic classification in acute myeloid leukaemia: Determination of prognostic significance of rarer recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK Medical Research Council trials

R. Hills, D. Grimwade, C. Harrison, 2010 .

Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia.

P. Sonneveld, E. Vellenga, A. Gratwohl, 2000, The hematology journal : the official journal of the European Haematology Association.

Identification of the t(15;17) in AML FAB types other than M3: evaluation of the role of molecular screening for the PML/RARα rearrangement in newly diagnosed AML

B. Bain, P. Freemont, S. Langabeer, 1999 .

Identification of the t(15;17) in AML FAB types other than M3: evaluation of the role of molecular screening for the PML/RARalpha rearrangement in newly diagnosed AML. The Medical Research Council (MRC) Adult Leukaemia Working Party.

B. Bain, P. Freemont, P. Freemont, 1999, British journal of haematology.

The clinical impact of mutant DNMT3A R882 variant allele frequency in acute myeloid leukaemia

R. Hills, D. Linch, A. Burnett, 2020, British journal of haematology.

Analysis of the clinical impact of NPM1 mutant allele burden in a large cohort of younger adult patients with acute myeloid leukaemia

R. Hills, N. Russell, D. Linch, 2019, British journal of haematology.

Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council.

R. Gray, R. Gray, A. Goldstone, 1997, Blood.

Prevention of graft-versus-host disease by ex vivo T cell depletion: reduction in graft failure with augmented total body irradiation.

S. Mackinnon, A. Burnett, H. Hambley, 1988, Leukemia.

ASXL1 mutations are infrequent in young patients with primary acute myeloid leukemia and their detection has a limited role in therapeutic risk stratification

R. Hills, D. Linch, Akbar Ali, 2014, Leukemia & lymphoma.

Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect

P. Johnson, A. Burnett, S. Rule, 2006, Bone Marrow Transplantation.

An In Vivo and In Vitro Comparison of the Effects of b2-a2 and b3-a2 p210BCR-ABL Splice Variants on Murine 32D Cells

K. Mills, A. Burnett, A. Gilkes, 2000, Leukemia and Lymphoma.

Abnormal TCR V/3 repertoire in patients with chronic myeloid leukaemia

A. Burnett, T. Hoy, S. H. Lim, 1995, British journal of haematology.

Del (9q) AML: clinical and cytological characteristics and prognostic implications

L. Side, C. Harrison, J. Boultwood, 2005, British journal of haematology.

Use of the polymerase chain reaction to monitor engraftment following allogeneic bone marrow transplantation.

K. Mills, E. Chalmers, A. Burnett, 1990, Bone marrow transplantation.

Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling.

R. Hills, P. White, N. Marquez, 2013, Blood.

Analysis of Rejection in HLA Matched T-Depleted Bone Marrow Transplants

J. Gribben, G. Janossy, J. Goldman, 1985 .

Acute leukemia in adolescents and young adults.

S. Hunger, A. Advani, A. Burnett, 2009, Seminars in oncology.

Unravelling an HLA-DR association in childhood acute lymphoblastic leukemia.

K. Mills, A. Burnett, C. Darke, 1999, Blood.

Neisseria Catarrhalis Septicaemia in Acute Lymphoblastic Leukaemia

A. Burnett, R. Rowan, A. M. Gordon, 1975, Scottish medical journal.

Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials

Keith Wheatley, Anthony V Moorman, A. Moorman, 2009, British journal of haematology.

The prognostic significance of IDH2 mutations in AML depends on the location of the mutation.

R. Hills, D. Linch, A. Burnett, 2011, Blood.

The ATRA Question In AML: Lack Of Benefit Overall Or In Any Molecular Subgroup In The NCRI AML16 Trial

R. Hills, N. Russell, L. Kjeldsen, 2013 .

EVI1 expression in acute myeloid leukaemia

B. Bain, S. Langabeer, D. Grimwade, 2001, British journal of haematology.

Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.

R. Hills, N. Russell, R. Clark, 2015, The Lancet. Oncology.

Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: evaluation of PML-RAR alpha and RAR alpha-PML assessment in patients who ultimately relapse.

S. Langabeer, D. Grimwade, E. Solomon, 1996, Leukemia.

The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial

R. Hills, N. Russell, M. Dennis, 2009, British journal of haematology.

Nucleic acid composition of bone marrow mononuclear cells in cobalamin deficiency

B. Ramsahoye, A. Burnett, C. Taylor, 1996 .

Methylation of the major breakpoint cluster region (M-bcr) in Philadelphia-positive CML.

K. Mills, A. Burnett, A. Sproul, 1993, Leukemia.

Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia.

Eleanor Woodward, G. Mufti, K. Mills, 2005, Biochemical and biophysical research communications.

Co-Existence of LMPP-Like and GMP-Like Leukemia Stem Cells In Acute Myeloid Leukemia

P. Woll, P. Vyas, A. Mead, 2010 .

Treatment intensification with FLAG‐Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long‐term follow up of the MRC AML15 trial

R. Hills, N. Russell, M. Dennis, 2021, British Journal of Haematology.

Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study *

E. Estey, J. Esteve, R. Schlenk, 2021, British journal of haematology.

Does BCR/ABL1 positive Acute Myeloid Leukaemia Exist?

R. Hills, N. Russell, D. Linch, 2013, British journal of haematology.

AC220 (Quizartinib) Can Be Safely Combined With Conventional Chemotherapy In Older Patients With Newly Diagnosed Acute Myeloid Leukaemia: Experience From The AML18 Pilot Trial

R. Hills, N. Russell, R. Clark, 2013 .

CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia

R. Hills, A. Burnett, E. Wang, 2011, Leukemia.

Impact of diagnostic cytogenetics on outcome in AML: Analysis of 1,613 patients entered into the UK MRC AML 10 trial.

R. Gray, D. Grimwade, C. Harrison, 1996 .

The tumour antigens RAGE‐1 and MGEA6 are expressed more frequently in the less lineage restricted subgroups of presentation acute myeloid leukaemia

K. Mills, A. Burnett, B. Guinn, 2006, British journal of haematology.

Therapy for isocitrate dehydrogenase 2 (IDH2)R172‐mutant acute myeloid leukaemia

R. Hills, N. Russell, D. Linch, 2021, British journal of haematology.

Randomized placebo‐controlled trial of granulocyte colony stimulating factor (G‐CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party

A. Goldstone, A. Burnett, K. Wheatley, 2009, British journal of haematology.

Autologous transplantation in acute leukemias, including purging.

A. Burnett, 1990, Current Opinion in Oncology.

The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: Preliminary analysis of 1115 patients in the MRC AML15 trial.

R. Hills, N. Russell, A. Hunter, 2006 .

Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia

P. Vyas, C. Bradbury, R. Hills, 2016, PloS one.

Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML

D. Linch, A. Burnett, 2007 .

Favorable results of allogeneic bone marrow transplantation (BMT) for adults with Philadelphia (Ph)-chromosome-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR): Results from the International ALL trial (MRC UKALL XII/ECOG E2993).

M. Tallman, S. Richards, H. Lazarus, 2001 .

A Phase Ib Study Combining the mTOR Inhibitor Everolimus (RAD001) with Low-Dose Cytarabine In Untreated Elderly AML

R. Hills, A. Wei, A. Burnett, 2010 .

European LeukemiaNet recommendations from an international expert panel , on behalf of the Diagnosis and management of acute myeloid leukemia in adults :

C. Bloomfield, E. Estey, T. Naoe, 2009 .

Targeting treatment in AML.

A. Burnett, S. Knapper, 2007, Hematology. American Society of Hematology. Education Program.

Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial

P. Sonneveld, E. van den Berg, B. van der Holt, 2007, British journal of haematology.

Alternative effects of RAS and RAF oncogenes on the proliferation and apoptosis of factor-dependent FDC-P1 cells.

A. McGlynn, A. Burnett, R. Darley, 2000, Leukemia research.

Screening for retinoic acid receptor alpha (RAR alpha) rearrangements in non-APL identifies a novel fusion gene in CMML

C. Bastard, S. McKenna, C. Chomienne, 1998 .

The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib.

J. Armand, J. Drach, J. S. San Miguel, 2007, The oncologist.

The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells

C. Fegan, A. Burnett, C. Pepper, 2012, Oncotarget.

The HSP90 inhibitor NVP‐AUY922‐AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells

M. Lazenby, A. Burnett, S. Knapper, 2013, British journal of haematology.

An immunophenotypic pre‐treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38low blasts

P. Vyas, R. Hills, N. Russell, 2015, British journal of haematology.

Who Should Be Transplanted in First Remission of Acute Myeloid Leukaemia?

R. Hills, A. Burnett, 2011, Current treatment options in oncology.

WTX is rarely mutated in acute myeloid leukemia

T. A. Lister, J. Fitzgibbon, K. Mills, 2008, Haematologica.

Mutations in a Large Cohort of Young Adult Patients with Core Binding Factor Acute Myeloid Leukemia: Impact on Outcome and the Selection of Patients for Alternative Treatment Including Transplantation in First Complete Remission

R. Hills, D. Linch, A. Moorman, 2011 .

Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials

D C Linch, K Wheatley, S. Langabeer, 1997, British journal of haematology.

Frequency of CBFβ/MYH11 fusion transcripts in patients entered into the U.K. MRC AML trials

S. Langabeer, D. Linch, A. Goldstone, 1997 .

Quizartinib Significantly Improves Overall Survival in FLT3-ITD Positive AML Patients Relapsed after Stem Cell Transplantation or after Failure of Salvage Chemotherapy: A Comparison with Historical AML Database (UK NCRI data)

R. Hills, A. Burnett, G. Gammon, 2015 .

Infective Endocarditis as a Complication of a Permanent Indwelling Right Atrial Catheter in a Patient with Severe Aplastic Anaemia

A. Burnett, I. Simpson, A. E. Morrison, 1988, Scottish medical journal.

Absence of bcr rearrangement and bcr/abl RNA in a patient with a 31-year survival of CML.

K. Mills, A. Burnett, A. Sproul, 1990, Leukemia.

Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease.

Adam J Mead, Robert K Hills, A. Mead, 2008, Blood.

Clofarabine in previously untreated elderly (>65 yrs) AML patients with an unfavourable cytogenetic profile who are considered unfit for standard intensive chemotherapy.

M. Baccarani, N. Russell, A. Burnett, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse

A. Burnett, S. Knapper, S. Man, 2015, Leukemia.

A Phase I Study of CHR-2797, an Orally Active Aminopeptidase Inhibitor in Elderly and/or Treatment Refractory Patients with Acute Myeloid Leukemia or Multiple Myeloma.

G. Morgan, P. Sonneveld, F. Davies, 2007 .

High-dose cyclophosphamide and VP 16 as late dosage intensification therapy for small cell carcinoma of lung

R. Stevenson, N. Lucie, D. Cunningham, 2004, Cancer Chemotherapy and Pharmacology.

THIRD PARTY MEDIATED GRAFT REJECTION DESPITE IRRADIATION OF BLOOD PRODUCTS

A. Burnett, A. Sproul, E. Simpson, 1992, British journal of haematology.

Treatment of Acute Leukaemias – New Directions for Clinical Research

A. Burnett, 2003 .

Standard Consolidation/Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII/ECOG E2993)

M. Tallman, S. Richards, G. Dewald, 2008 .

Reasons For Survival Improvement In Core Binding Factor AML: A 25 Year Analysis Of The UK MRC/NCRI AML Trials

R. Hills, N. Russell, R. Clark, 2013 .

Philadelphia chromosome plus ve patients with adult acute lymphoblastic leukaemia (ALL), early results from the international ALL trial (MRC UKALL-XII/ECOG E2993).

D. Neuberg, M. Tallman, S. Richards, 1999 .

A phase II study (Biov-121) of clofarabine monotherapy first line in patients aged 65 years or older with acute myeloid leukemia for whom standard intensive chemotherapy is not considered suitable.

M. Baccarani, R. Hills, N. Russell, 2006 .

A Randomised Evaluation of Low-Dose Cytarabine Arabinoside Plus Lenalidomide Versus Single-Agent Low-Dose Cytarabine Arabinoside in Older Patients with Acute Myeloid Leukaemia: Results from the LI-1 Trial

R. Hills, N. Russell, M. Dennis, 2021, Blood.

Serum-free culture of human megakaryocyte progenitors.

A. Burnett, G. Masters, 1997, Clinical and Laboratory Haematology.

The dielectrophoresis enrichment of CD34+ cells from peripheral blood stem cell harvests.

R. Pethig, K. Mills, M. Talary, 1996, Bone marrow transplantation.

Response rate and bridging to hematopoietic stem cell transplantation (HSCT) with quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed/refractory AML after second-line chemotherapy or previous bone marrow transplant.

E. Estey, H. Döhner, H. Dombret, 2013 .

Increased Plasma FLT3 Ligand Levels Following Chemotherapy May Interfere with the Clinical Efficacy of FLT3 Inhibitors.

P. White, M. Levis, A. Burnett, 2009 .

The relationship between FLT3 mutation status: biological characteristics and outcome in patients with acute promyelocytic leukaemia.

R. Hills, K. Mills, D. Grimwade, 2003 .

Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia.

Gos Micklem, Berthold Göttgens, George S Vassiliou, 2012, Blood.

Pre-Transplant NPM1 Mutant Transcript Level Is Highly Predictive of Outcome after Allograft and Thresholds Are Dependent on FLT3 ITD Status

N. Potter, R. Hills, N. Russell, 2018, Blood.

Long-term results of the MRC AML10 trial.

R. Hills, A. Goldstone, A. Burnett, 2006, Clinical advances in hematology & oncology : H&O.

Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients.

E. Estey, R. Hills, F. Appelbaum, 2013, Blood.

European leukemianet-integration of the leading national leukemia networks (CML, AML, ALL, CLL, MDS, CMPD) another interdisciplinary partner groups in Europe

T. Haferlach, M. Baccarani, U. Mansmann, 2007 .

Allelic loss of the FMS gene in acute myeloid leukaemia.

A. Burnett, H. McGlynn, A. Baker, 1997, Leukemia research.

Adult patients with acute lymphoblastic leukemia (ALL) and central nervous system (CNS) leukemia at diagnosis may attain durable complete remissions (CR). Results from the international ALL trial (MRC UKALL-XII/ECOG E2993)

M. Tallman, S. Richards, R. Chopra, 2004 .

The outcome of 551 1(st) CR transplants in adult ALL from the UKALL XII/ECOG 2993 study

M. Tallman, S. Richards, R. Chopra, 2004 .

Amplification and sequencing of genomic breakpoints located within the M-bcr region by Vectorette-mediated polymerase chain reaction.

P. Elvin, K. Mills, A. Burnett, 1992, Leukemia.

Outcome of acute myeloid leukaemias affecting core binding factor subunits: the UK MRC experience

S. Langabeer, D. Linch, A. Burnett, 1997 .

Acute myeloid leukemia.

J. Downing, B. Löwenberg, A. Burnett, 1999, The New England journal of medicine.

Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia

Lara E. Sucheston-Campbell, C. Gieger, A. Skol, 2022, Nature communications.

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.

R. Clark, M. Levis, D. Small, 2004 .

Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993.

M. Tallman, S. Richards, R. Chopra, 2006, Blood.

L. Staudt, D. Weisenburger, J. Vose, 2008 .

Additional impact of mutational genotype on prognostic determination in resistant and relapsed acute myeloid leukaemia.

R. Hills, N. Russell, D. Linch, 2021, Leukemia research.

TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis

R. Hills, D. Linch, D. Bowen, 2009, Leukemia.

Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial

R. Hills, N. Russell, L. Kjeldsen, 2018, Haematologica.

CEP701 and PKC412 Predictably and Reliably Inhibit FLT3 Phosphorylation in Primary AML Blasts but Their Induction of a Cytotoxic Response Appears to Be Much More Variable.

K. Mills, A. Burnett, A. Gilkes, 2004 .

Acute Promyelocytic Leukemia Characterization of Cryptic Rearrangements and Variant Translocations in

D. Sheer, S. Langabeer, P. Gorman, 2013 .

Introduction: Modern management of acute myeloid leukemia.

A. Burnett, 2001, Seminars in hematology.

A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia

R. Hills, N. Russell, R. Clark, 2015, Leukemia.

Outcomes of older patients experiencing reduced intensity conditioning allograft: results of the NCRI AML16 trial

C. Craddock, R. Hills, N. Russell, 2015 .

The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial

R. Hills, M. Lazenby, A. Burnett, 2014, Leukemia.

Reply to D. Przepiorka et al and M.K. Jensen.

R. Hills, A. Burnett, 2013, Journal of Clinical Oncology.

A phase 2 trial of the FLT 3 inhibitor lestaurtinib ( CEP 701 ) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

M. Levis, D. Small, R. Chopra, 2006 .

Low-dose recombinant alfa-2a-interferon: a feasible maintenance therapy in acute myeloid leukaemia in the older patient.

A. Goldstone, A. Burnett, D. Milligan, 1993, Acta haematologica.

recommendations from an international expert panel, on behalf of the Diagnosis and management of acute myeloid leukemia in adults:

C. Bloomfield, E. Estey, T. Naoe, 2010 .

Effect of quizartinib (AC220) on response rates and long-term survival in elderly patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia.

E. Estey, H. Dombret, G. Martinelli, 2013 .

A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia

R. Hills, N. Russell, M. Dennis, 2016, Leukemia.

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia.

A. Rohatiner, R. Clark, A. Hunter, 2003, Blood.

R. Hills, D. Grimwade, C. Harrison, 2010, Blood.

Younger Adult Acute Myeloid Leukemia (AML) Patients with IDH2-R140 Mutations Have a Significantly Better Prognosis Than Those with Either IDH2-R172 or IDH1 Mutations

R. Hills, D. Linch, A. Burnett, 2010 .

The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status.

R. Hills, D. Linch, A. Burnett, 2010, Blood.

Therapeutic advances in acute myeloid leukemia.

B. Löwenberg, A. Burnett, M. Wetzler, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial

R. Hills, N. Russell, R. Clark, 2016, Haematologica.

New induction and postinduction strategies in acute myeloid leukemia

A. Burnett, 2012, Current opinion in hematology.

Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia.

R. Hills, A. Khwaja, D. Linch, 2014, Blood.

MYELOID NEOPLASIA Impact of FLT3 ITD mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia

R. Hills, A. Khwaja, D. Linch, 2014 .

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML.

R. Hills, R. Clark, A. Burnett, 2018, Blood advances.

The prognostic significance of IDH2 mutations in AML depends on the location of the mutation.

R. Hills, D. Linch, A. Burnett, 2011, Blood.

Abnormalities of adherent layers grown from bone marrow of patients with myelodysplasia

K. Mills, A. Burnett, G. B. Tennant, 2000, British journal of haematology.

Identification of transcription factors expressed during ATRA‐induced neutrophil differentiation of HL60 cells

Brown, Walsh, K. Mills, 1998, British journal of haematology.

Ras-induced reactive oxygen species promote growth factor-independent proliferation in human CD34+ hematopoietic progenitor cells.

A. Burnett, P. James, R. Darley, 2010, Blood.

Mutant N-RAS Induces Erythroid Lineage Dysplasia in Human CD34+ Cells

A. Burnett, R. Darley, T. Hoy, 1997, The Journal of experimental medicine.

Autologous BMT for AML without purging.

A. Burnett, 1989, Bone marrow transplantation.

Tris(8-hydroxyquinolinato)gallium(III)-loaded copolymer micelles as cytotoxic nanoconstructs for cosolvent-free organometallic drug delivery.

A. Collins, S. Mann, A. Burnett, 2011, Small.

No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials.

R. Hills, N. Russell, N. Khan, 2018, Blood.

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.

W. Jędrzejczak, H. Dombret, G. Martinelli, 2007, Blood.

Tipifarnib in acute myeloid leukemia.

A. Burnett, J. Kell, 2007, Drugs of today.

Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation

W. Siegert, C. Gisselbrecht, P. Biron, 1994, The Lancet.

A C-terminal FMS mutation in a patient with B-cell malignancy.

A. Burnett, S. Ball, J. Whittaker, 1995, Leukemia.

Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia.

N. Russell, M. Grunwald, M. Levis, 2019, Blood advances.